-- In response to the growing demand for cancer immunotherapy, Alfa Cytology today announced the launch of an integrated oncolytic bacterial therapy one-stop development platform. The platform relies on professional in vivo pharmacodynamic evaluation laboratories and provides high-quality Oncology Drug Discovery CRO Services to solve the problems of strain targeting and transformation evaluation.
The development of oncolytic bacterial therapy involves strain screening, genetic engineering, and preclinical evaluation. Based on the OncoBact™ technology platform, Alfa Cytology integrates resources to support the research team to complete the systematic research from screening to in vivo validation, help the research team to complete the whole process development from strain engineering to efficacy verification under a unified platform, and fill the gap between basic research and clinical translation.
In this one-stop platform, Alfa Cytology used synthetic biology and gene editing to support strain candidate development and design bacterial vectors that can selectively proliferate in response to the tumor microenvironment. At the same time, the platform supports multimodal load delivery research and regulates bacterial survival and clearance through biosafety strategies. These research and development data laid the experimental foundation for the subsequent development of Investigator Initiated Trial Support Services.
Based on the in vivo functional verification, Alfa Cytology established an in vivo efficacy evaluation laboratory to systematically analyze the targeting ability, efficacy, and safety of oncolytic bacteria. By constructing orthotopic, metastatic, and PDX tumor models, growth monitoring, microenvironment analysis, and bacterial distribution study were carried out in the laboratory. These experiments not only provide the basis for optimizing treatment strategies but also provide the necessary safety assessments for investigator-initiated clinical exploration (IIT).
In addition, the platform supports the research of combination treatment strategies and constructs an integrated system covering strain modification and functional screening. Research teams can complete core data validation on the same platform, which helps to shorten the development cycle and reduce the risk of translation.
"Preclinical validation data are essential to evaluate treatment strategies," said a spokesperson for Alfa Cytology. "By integrating a one-stop development system with in vivo evaluation Services, we are committed to supporting innovative research and helping our clients build efficient research processes through specialized Investigator Initiated Trial Support Services."
About Alfa Cytology
Alfa Cytology focuses on preclinical research of cancer immunotherapy and innovative treatment strategies, providing systematic solutions for global biotechnology companies and scientific research institutions. The company uses professional Oncology Drug Discovery CRO Services to provide experimental system support for a variety of anti-tumor technologies and accelerate the process of transformation from laboratory to clinical practice.
Contact Info:
Name: Toya Davis
Email: Send Email
Organization: Alfa Cytology
Website: https://www.alfacytology.com/
Release ID: 89193271
Google
RSS